全球關節止痛注射市場：市場規模、佔有率、成長分析、依類型、應用分類 - 產業預測，2023-2030 年

Global Joint Pain Injections Market Size, Share, Growth Analysis, By Type(corticosteroids, hyaluronic acid), By Application(osteoarthritis, rheumatoid arthritis) - Industry Forecast 2023-2030

出版日期: 2023年11月18日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2021年全球關節止痛注射劑市場規模為63億美元，從2022年的67.9億美元成長到2030年的122.8億美元，預計在預測期內（2023-2030年）將以複合年成長率7.7%成長。

由於關節相關疾病盛行率的增加、老年人口的增加以及對微創替代治療的需求不斷增加等主要因素，全球關節止痛注射市場正在經歷顯著成長。關節止痛注射可以針對性地緩解疼痛並改善關節功能，是手術介入的可行替代方案。該市場的注射技術不斷進步，不斷開發新產品以提高功效和耐用性。此外，再生醫學和生物製藥的日益接受度正在對市場形勢產生重大影響。儘管有這些積極的趨勢，但注射高成本、報銷範圍有限和潛在副作用等課題仍然可能阻礙整體市場的成長。

自上而下和自下而上的方法已用於預測和檢驗關節止痛注射劑的全球市場規模，並預測其他各個相關子市場的市場規模。用於估計市場規模的調查方法包括以下詳細資訊：用於確定市場主要企業的二次研究，以及用於確定每個地區的市場佔有率的主要和二次研究。整個過程包括研究主要企業的年度和財務報告以及廣泛的採訪，以獲得執行長、副總裁、董事和行銷負責人等行業領導者的重要見解。所有佔有率比率和細目分類均使用二手資訊確定並使用主要資訊檢驗。本研究涵蓋的所有可能影響市場的參數都經過了考慮、詳細研究、初步研究檢驗和分析，以獲得最終的定量和定性資料。

全球關節止痛注射劑區隔市場分析

關節止痛注射劑的全球市場依類型、應用和地區區隔。依類型分為皮質類固醇、玻尿酸、富血小板血漿（PRP）、幹細胞等。依應用，市場分為骨關節炎、類風濕性關節炎、痛風和其他關節相關疾病。依地區分類，分為北美、歐洲、亞太地區、中東/非洲、拉丁美洲。

全球關節痛注射市場的促進因素

全球關節止痛注射市場是由關節相關疾病日益普及所推動的。骨關節炎和類類風濕性關節炎等疾病正在增加，對關節止痛注射等有效的疼痛管理解決方案產生了巨大的需求。老年人口的增加、久坐的生活方式以及運動相關傷害的增加是促進市場成長的因素。

全球關節止痛注射劑市場的抑制因素

治療成本高：全球關節止痛注射劑市場的一個重要抑制因素是與治療相關的高成本。關節止痛注射的費用可能會限制保險不足的個人獲得治療的機會，特別是在醫療保健費用令人擔憂的地區。此外，某些國家的報銷政策和監管障礙是市場成長的潛在障礙。

關節止痛注射劑的全球市場趨勢

擴大採用微創手術：全球關節止痛注射市場的一個主要趨勢是擴大採用微創手術。患者和醫療保健提供者擴大選擇非手術治療關節疼痛，推動注射作為治療選擇的普及。微創手術（包括關節止痛注射）具有恢復時間更快、併發症風險更低和術後疼痛更少等優點。這些門診注射透過直接向受影響的關節給藥來提供有針對性的疼痛緩解。這一趨勢與對個體化、以患者為中心的護理日益成長的需求相吻合，從而可以根據每位患者的具體需求制定個性化的治療計劃。

執行摘要
調查方法
母市場分析
主要市場考察
- 技術分析
- 價格分析
- 供應鏈分析
- 價值鏈分析
- 市場生態系統
- 智慧財產權分析
- 貿易分析
- Start-Ups分析
- 原料分析
- 創新矩陣
- 研發線產品分析
- 總體經濟指標
- 主要投資分析
- 關鍵成功因素
- 競爭程度
市場動態及展望
- 市場動態
  - 促進因素
  - 機會
  - 抑制因素
  - 任務
- 監管形勢
- 波特的分析
- 對未來中斷的特殊考察
全球關節止痛注射市場：依類型
- 市場概況
- 皮質類固醇
- 玻尿酸
- 富血小板血漿 (PRP)
- 幹細胞
- 其他
關節止痛注射劑的全球市場：依應用分類
- 市場概況
- 骨關節炎
- 類風濕性關節炎
- 痛風
- 其他關節相關疾病
全球關節止痛注射劑市場規模：依地區分類
- 市場概況
- 北美洲
  - 美國
  - 加拿大
- 歐洲
  - 德國
  - 西班牙
  - 法國
  - 英國
  - 其他歐洲國家地區
- 亞太地區
  - 中國
  - 印度
  - 日本
  - 韓國
  - 其他亞太地區
- 拉丁美洲
  - 巴西
  - 其他拉丁美洲地區
- 中東和非洲 (MEA)
  - 海灣合作理事會國家
  - 南非
  - 其他中東/非洲地區
競爭形勢
- 前5名企業對比
- 主要企業市場定位（2021年）
- 主要市場參與者所採取的策略
- 關鍵成功策略
- 近期市集活動
- 主要企業市場佔有率（2021年）
主要企業簡介
- Johnson & Johnson
- Pfizer Inc.
- Sanofi
- Novartis AG
- Eli Lilly and Company
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Roche Holding AG
- AbbVie Inc.
- AstraZeneca plc
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Celgene Corporation
- Gilead Sciences, Inc.
- Grunenthal GmbH
- Mylan NV
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited

簡介目錄

Product Code: SQMIG35I2165

Global Joint Pain Injections Market size was valued at USD 6.3 billion in 2021 and is poised to grow from USD 6.79 billion in 2022 to USD 12.28 billion by 2030, growing at a CAGR of 7.7% in the forecast period (2023-2030).

The global market for Joint Pain Injections is undergoing substantial growth driven by key factors such as the increasing prevalence of joint-related disorders, a growing geriatric population, and a rising demand for minimally invasive treatment alternatives. Joint pain injections, offering targeted pain relief and improved joint function, serve as a viable option to surgical interventions. The market is marked by ongoing advancements in injection technologies and the formulation of new products aimed at enhancing efficacy and durability. Furthermore, the increasing acceptance of regenerative medicine and biologic injections is significantly influencing the market landscape. Despite these positive trends, challenges including the high cost of injections, limited reimbursement coverage, and potential side effects pose considerations that may impede the overall growth of the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Joint Pain Injections Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Global Joint Pain Injections Market Segmental Analysis

The Global Joint Pain Injections Market is segmented by type, application, and region. Based on type, the market can be segmented into include corticosteroids, hyaluronic acid, platelet-rich plasma (PRP), stem cells, and others. Based on application, the market is segmented into osteoarthritis, rheumatoid arthritis, gout, and other joint-related disorders. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Joint Pain Injections Market

The global Joint Pain Injections market is propelled by the increasing prevalence of joint-related disorders. Conditions like osteoarthritis and rheumatoid arthritis are on the rise, creating a substantial demand for effective pain management solutions, notably joint pain injections. Contributing factors include the growing aging population, sedentary lifestyles, and an escalation in sports-related injuries, collectively fostering market growth.

Restraints in the Global Joint Pain Injections Market

High Cost of Treatment: A notable restraint in the global Joint Pain Injections market is the high cost associated with treatment. The expense of joint pain injections, particularly for individuals lacking sufficient insurance coverage, can limit access to these treatments, particularly in regions where healthcare affordability is a concern. Additionally, reimbursement policies and regulatory hurdles in certain countries pose potential obstacles to market growth.

Market Trends of the Global Joint Pain Injections Market

Increasing Adoption of Minimally Invasive Procedures: A significant trend in the global Joint Pain Injections market is the rising adoption of minimally invasive procedures. Patients and healthcare providers are increasingly opting for non-surgical alternatives in managing joint pain, driving the popularity of injections as a treatment option. Minimally invasive procedures, including joint pain injections, offer advantages such as shorter recovery times, reduced risk of complications, and diminished postoperative pain. Administered in outpatient settings, these injections provide targeted pain relief by delivering medications directly to the affected joint. This trend aligns with the growing demand for personalized and patient-centric care, allowing for individualized treatment plans tailored to each patient's specific needs.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
  - Drivers
  - Opportunities
  - Restraints
  - Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
  - Drivers
  - Opportunities
  - Restraints
  - Challenges
- Regulatory Landscape
- Porters Analysis
  - Competitive rivalry
  - Threat of Substitute Products
  - Bargaining Power of Buyers
  - Threat of New Entrants
  - Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
  - Political Impact
  - Economic Impact
  - Social Impact
  - Technical Impact
  - Environmental Impact
  - Legal Impact
Global Joint Pain Injections Market by Type
- Market Overview
- corticosteroids
- hyaluronic acid
- platelet-rich plasma (PRP)
- stem cells
- and others
Global Joint Pain Injections Market by Application
- Market Overview
- osteoarthritis
- rheumatoid arthritis
- gout
- and other joint-related disorders
Global Joint Pain Injections Market Size by Region
- Market Overview
- North America
  - USA
  - Canada
- Europe
  - Germany
  - Spain
  - France
  - UK
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - South Korea
  - Rest of Asia-Pacific
- Latin America
  - Brazil
  - Rest of Latin America
- Middle East & Africa (MEA)
  - GCC Countries
  - South Africa
  - Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
  - By Development
  - By Company
  - By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Johnson & Johnson (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Pfizer Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Sanofi (France)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Novartis AG (Switzerland)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Eli Lilly and Company (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Merck & Co., Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- GlaxoSmithKline plc (United Kingdom)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Roche Holding AG (Switzerland)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- AbbVie Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- AstraZeneca plc (United Kingdom)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Bayer AG (Germany)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Boehringer Ingelheim International GmbH (Germany)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Bristol-Myers Squibb Company (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Celgene Corporation (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Gilead Sciences, Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Grunenthal GmbH (Germany)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Mylan N.V. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Sun Pharmaceutical Industries Ltd. (India)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments